Status:
COMPLETED
D-chiroinositol Administration in Hypogonadal Males
Lead Sponsor:
Lo.Li.Pharma s.r.l
Conditions:
Male Hypogonadism
Sexual Dysfunction
Eligibility:
MALE
65-75 years
Phase:
NA
Brief Summary
D-chiroinositol (DCI), is known as second messenger of insulin pathway, but recently several works have reported the influence of DCI on steroidogenesis. In particular, the DCI capabilities to regulat...
Eligibility Criteria
Inclusion
- Men, with a diagnosis of Late-Onset Male Hypogonadism
- Insulin resistance (HOMA Index \> 2,5)
- BMI between 25 and 30
Exclusion
- Alcohol intake and/or drug abuse
- Recent hormonal treatment
- Smoking
- Obesity
- Systemic or endocrine diseases
- Male accessory gland infection
- Clinical history of cryptorchidism or varicocele and micro-orchidism
Key Trial Info
Start Date :
January 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04708249
Start Date
January 18 2021
End Date
March 1 2021
Last Update
March 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinica Alma Res
Rome, Italy, 00198